“…Since prostaglandin E~ was first used by Carlson in 1973 [3,4], its effectiveness has been proved in many clinical studies [1,[6][7][8]12,13,16,17]. The mode of action relies on vasodilation, improvement of erythrocyte flexibility, inhibition of ischemia-induced neutrophil activation, reduction of platelet aggregation, and increased fibrinolytic activity [2,14,15].…”